SEngine test – pro
SEngine’s high-throughput technology simultaneously tests more than 200 cancer drugs against a patient’s unique tumor organoid outside the body. The results putatively decode the most effective and least toxic treatment options that DNA sequencing alone cannot reveal. The proprietary platform leverages the aggregated, anonymized test results to develop new cancer-fighting drugs. SEngine test ranks fit of a medicaiotn to the patient on two dimensions: Personalization and Sensitivity. Personaluization is a proprietary measure of how well this patient responds to a specific drug relative toother patients’ tests as per the test provider’s internal database. Lower values indicate better response.
As far as I can determine, this methodology ahd not been validated or prospectively tests.
Gray HJ, Chatterjee P, Rosati R, Appleyard LR, Durenberger GJ, Diaz RL, Swan HA, Peretti D, Pollastro M, Ainge T, Kapeli K, Pereira S, Margossian AL, Banda K, Goff BA, Swisher EM, Bernard B, Kemp CJ, Grandori C. Extraordinary clinical response to ibrutinib in low-grade ovarian cancer guided by organoid drug testing. NPJ Precis Oncol. 2023 May 18;7(1):45.
King DA, Smith AR, Pineda G, Nakano M, Michelini F, Goedegebuure SP, Thyparambil S, Liao WL, McCormick A, Ju J, Cioffi M, Zhang X, Hundal J, Griffith M, Grandori C, Pollastro M, Rosati R, Margossian A, Chatterjee P, Ainge T, Flory M, Ocampo P, Chen LM, Poultsides GA, Baron AD, Chang DT, Herman JM, Gillanders WE, Park H, Hoos WA, Nichols M, Fisher GA, Kuo CJ. Complete Remission of Widely Metastatic Human Epidermal Growth Factor Receptor 2-Amplified Pancreatic Adenocarcinoma After Precision Immune and Targeted Therapy With Description of Sequencing and Organoid Correlates. JCO Precis Oncol. 2023 Apr;7
Predictive value of a CLIA-approved organoid based drug sensitivity test. Abs https://meetings.asco.org/abstracts-presentations/188186